RESUMEN
Twelve asthmatic patients were selected for this trial. Clinical al1d spirometric lung function assessments were carried out weekly before, during and after (4) weeks of Beclomethasone therapy. Symptom diary score charts were provided to the patients and were ins ructed to note their symptoms and bronchodilator usage daily. In 55.5 percent of patients there were statistically significant Improvements in pulmonary function para-meters which were accompanied by clinical improvement in 66 percent of patients during Beclomethasone therapy. There were reduction ill bronchodilator requirements together with reduction in diary scores in 66 percent of patients. None required systemic steroids during Beclomethasone therapy. 87 percent of patients claimed benefit except one in whom there was no remarkable improvement in clinical as well as in spirometric lung function assessments No side effects attributable to Beclomethasone dipropionate therapy were noted. Beclomethasone dipropionate aerosol is valuable in the treatment of asthma especially in those becoming worse and who are no longer responding adequately to bronchodilators, because of its topical potency and lack of systemic side effects and so enabling us to avoid the use of. systemic steroid therapy.